Background:
β-thalassemia
is
an
autosomal
recessive
hereditary
hemoglobin
production
disorder
characterized
by
abnormal
synthesis.
The
efficient
and
safe
therapies
for
transfusion-dependent
(TDT)
patients
are
desperately
required
to
minimize
the
requirement
blood
transfusion.
Objective:
To
establish
safety
efficacy
of
low-dose
thalidomide
in
TDT
patients.
Methodology:
retrospective
cohort
study
was
conducted
Khyber
Medical
University,
Peshawar
Blood
Diseases
Clinic,
investigate
therapy
Samples
were
collected
from
diagnosed
cases
whose
ages
≥3
years
on
treatment
a
period
≥6
months.
Complete
count
CBC
performed
Sysmex
XP-100,
Japan
biochemical
tests
Cobas
6000
analyzer
series.
Comprehensive
patients’
demographics,
clinical
history
prognosis
data
recorded
analyzed
using
SPPS
27.
Results:
patient
characteristics,
parameters
hematological
response
assessed
statistically
tested
384
therapy.
Applying
criteria
Hb
level
achievement,
we
marked
significant
results
(<0.001)
Excellent,
Good,
Partial
responders
that
184
(47.9%),
96
(25%),
60
(15.6%),
respectively.
common
side
effects
observed
with
drug
included
abdominal
discomfort,
nausea,
vomiting,
headache,
constipation,
dizziness,
fatigue,
anxiety,
repeated
infections,
skin
rash,
controlled
symptomatic
and/or
dose
adjustment.
Conclusion:
Collectively,
effective
increasing
levels
thus
reducing
requirements
transfusion
Future
trials
suggested
strengthen
guidelines
its
rational
use
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 4, 2024
AbstractPurpose:
The
main
adverse
effects
of
paclitaxel
chemotherapy
are
arthralgia,
myalgia,
and
neuropathic
pain.
The
objective
this
research
was
to
assess
the
potential
preventive
benefits,
continuous
management
strategies,
likelihood
remission
recurrence
these
symptoms
after
Thalidomide
treatment.
Methods:
This
retrospective
study
reviewed
medical
histories
120
cancer
patients
who
experienced
pain
while
undergoing
at
First
People’s
Hospital
Yulin,
Guangxi,
from
March
2022
December
2023.
were
stratified
into
two
groups
according
whether
they
received
or
not:
with
(n
=
48)
without
34).
Pain
assessments
initiated
first
sign
during
initial
treatment
cycle
repeated
over
next
three
cycles
effectiveness
in
managing
its
capabilities.
employed
Common
Terminology
Criteria
for
Adverse
Events
(CTCAE)
painDETECT
questionnaire
measure
intensity
by
patients.
Findings:
At
study’s
inception,
score
21.17±2.69
group
20.24±2.47
non-Thalidomide
group.
Subsequent
follow-ups
revealed
a
dramatic
reduction
0.13±0.44
6.68±1.90
group..
Neuropathic
pain,
along
arthralgia
more
pronounced
baseline
third
cycle.
A
significant
difference
noted
between
(all
p<0.05).
Implications:
findings
indicate
that
is
effective
alleviating
paindue
paclitaxel.
preemptive
application
proved
be
exceptionally
potent
providing
rapid
relief.
monitoring
sustained
efficacy
across
multiple
cycles.
Background:
β-thalassemia
is
an
autosomal
recessive
hereditary
hemoglobin
production
disorder
characterized
by
abnormal
synthesis.
The
efficient
and
safe
therapies
for
transfusion-dependent
(TDT)
patients
are
desperately
required
to
minimize
the
requirement
blood
transfusion.
Objective:
To
establish
safety
efficacy
of
low-dose
thalidomide
in
TDT
patients.
Methodology:
retrospective
cohort
study
was
conducted
Khyber
Medical
University,
Peshawar
Blood
Diseases
Clinic,
investigate
therapy
Samples
were
collected
from
diagnosed
cases
whose
ages
≥3
years
on
treatment
a
period
≥6
months.
Complete
count
CBC
performed
Sysmex
XP-100,
Japan
biochemical
tests
Cobas
6000
analyzer
series.
Comprehensive
patients’
demographics,
clinical
history
prognosis
data
recorded
analyzed
using
SPPS
27.
Results:
patient
characteristics,
parameters
hematological
response
assessed
statistically
tested
384
therapy.
Applying
criteria
Hb
level
achievement,
we
marked
significant
results
(<0.001)
Excellent,
Good,
Partial
responders
that
184
(47.9%),
96
(25%),
60
(15.6%),
respectively.
common
side
effects
observed
with
drug
included
abdominal
discomfort,
nausea,
vomiting,
headache,
constipation,
dizziness,
fatigue,
anxiety,
repeated
infections,
skin
rash,
controlled
symptomatic
and/or
dose
adjustment.
Conclusion:
Collectively,
effective
increasing
levels
thus
reducing
requirements
transfusion
Future
trials
suggested
strengthen
guidelines
its
rational
use
